NCT01075321 · REGISTRY CONDITION SEARCH

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2020-10-22

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving everolimus together with lenalidomide may be an effective treatment for lymphoma. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving everolimus and lenalidomide together and to see how well they work in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Patients Reporting Dose-Limiting Toxicity (DLT) (Phase I)

→

outcome · POSTED

Best Response to Dose Level 0

→

outcome · POSTED

Overall Survival for All Eligible Patients

→

outcome · POSTED

Progression-Free Survival For All Eligible Patients

→

outcome · POSTED

Duration of Response for All Eligible Patients

→

outcome · POSTED

Time to Treatment Failure for All Eligible Patients

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion * Histological or cytological confirmation of relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma =\< 6 months prior to registration * The following disease types are eligible: Study 1 - Aggressive lymphomas- Transformed lymphomas; Diffuse large B cell lymphoma; Mantle cell lymphoma; Follicular lymphoma grade III; Precursor B lymphoblastic leukemia/lymphoma; Mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma/leukemia; Precursor T lymphoblastic leukemia/lymphoma; Primary cutaneous anaplastic large cell lymphoma; and Anaplastic large cell lymphoma-primary systemic type * Study 2- Indolent lymphomas: Follicular lymphoma, grades 1, 2; Extranodal marginal zone B-cell lymphoma of MALT type; Nodal marginal zone B-cell lymphoma; Splenic marginal zone B-cell lymphoma; Small lymphocytic lymphoma * Study 3- Uncommon lymphomas: Peripheral T cell lymphoma, unspecified; Anaplastic large cell lymphoma (T and null cell type); Lymphoplasmacytic lymphoma (Waldenstrom Macroglobulinemia); Post transplant lymphoproliferative disorders; Mycosis fungoides/Sezary syndrome; Hodgkin Disease; Primary effusion lymphoma; Adult T-cell leukemia/lymphoma; Extranodal NK/T-cell lymphoma, nasal type; Enteropathy-type T-cell lymphoma; Hepatosplenic T-cell lymphoma; Subcutaneous panniculitis-like T-cell lymphoma; Angioimmunoblastic T-cell lymphoma; Anaplastic large cell lymphoma-primary cutaneous type; and Blastic plasmacytoid dendritic cell neoplasm * Measurable disease by CT or MRI or PET/CT: Must have at least one lesion that has a single diameter of \>= 2 cm or tumor cells in the blood \>= 5 x10\^9/L (Skin lesions can be used if the area is \>= 2 cm in at least one diameter and photographed with a ruler) * For lymphoplasmacytic lymphoma patients without measurable lymphadenopathy, measurable disease is defined by both of the following criteria: Bone marrow lymphoplasmacytosis with \> 10% lymphoplasmacytic cells or aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy and quantitative IgM monoclonal protein \> 800 mg/dL * ANC \>= 1200/uL * Hgb \> 9 g/dl * PLT \>= 50,000/uL * Total bilirubin =\< 1.5 x upper limit of normal (ULN) or if total bilirubin is \> 1.5 x ULN the direct bilirubin must be normal * AST =\< 2.5 x ULN or AST =\< 5 x ULN if liver involvement * Creatinine =\< 1.5 x ULN * Creatinine clearance \>= 50mL/min (Cockcroft-Gault calculation) * Fasting serum cholesterol =\< 300 mg/dL OR =\< 7.75 mmol/L AND fasting triglycerides =\< 2.5 x ULN (NOTE: Lipid lowering medication is allowed) * ECOG Performance Status (PS) 0, 1, or 2 * Females of childbearing potential (FCBP) must have a negative serum pregnancy test with a sensitivity of at least 50 IU/ml within 10-14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide, during study treatment and for 8 weeks after the last dose of RAD001 (FCBP must also agree to ongoing pregnancy testing) * Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy (All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure) * Provide informed written consent * Willingness to return to Mayo Clinic enrolling institution for follow-up * Patient is willing to provide blood samples for research purposes * Recovered from acute side effects of prior myelosuppressive chemotherapy or biological therapy * All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist Exclusion * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Active other malignancy, excepting non-melanotic skin cancer or carcinoma-in-situ of the cervix (If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer) * History of myocardial infarction =\< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias * Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; Nursing women; Men or women of childbearing potential who are unwilling to employ adequate contraception throughout the study and for 8 weeks after the last dose of study drug (NOTE: If barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception) * Patients who have received prior treatment with both an mTOR inhibitor (sirolimus, temsirolimus, everolimus) and lenalidomide who did not have a response to either when used as single agents * Patients with a known allergic reaction to thalidomide, RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or their excipients to the point where either agent should not be given again * The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs * Known positive for HIV or infectious hepatitis, type A, B or C * Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study * Immunization with attenuated live vaccines within one week of study entry or during study period * Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) * Prior Allogeneic Stem Cell Transplant * No chronic treatment with systemic steroids or another immunosuppressive agents (at a dose equivalent of greater than 20 mg prednisone per day) or other immunosuppressive agents)
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: everolimus
Drug: lenalidomide
Other: laboratory biomarker analysis
Genetic: polymorphism analysis
Other: immunohistochemistry staining method
Genetic: microarray analysis
Genetic: fluorescence in situ hybridization
label
Arm I
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I
description
Given orally
name
everolimus
other Names
42-O-(2-hydroxy)ethyl rapamycin
Afinitor
RAD001
type
DRUG
arm Group Labels
Arm I
description
Given orally
name
lenalidomide
other Names
CC-5013
IMiD-1
Revlimid
type
DRUG
arm Group Labels
Arm I
description
Correlative studies
name
laboratory biomarker analysis
type
OTHER
arm Group Labels
Arm I
description
Correlative studies
name
polymorphism analysis
type
GENETIC
arm Group Labels
Arm I
description
Optional correlative studies
name
immunohistochemistry staining method
other Names
immunohistochemistry
type
OTHER
arm Group Labels
Arm I
description
Optional correlative studies
name
microarray analysis
other Names
gene expression profiling
type
GENETIC
arm Group Labels
Arm I
description
Optional correlative studies
name
fluorescence in situ hybridization
other Names
fluorescence in situ hybridization (FISH)
type
GENETIC

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 58
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The number of dose-limiting toxic events (DLT) for this combination of drug treatment will determine the Maximum Tolerated Dose (MTD) in subsequent phases of this study. The following events were defined as a DLT: a grade 4+ Neutropenia or platelet count decrease, a grade 4 infection, or any grade 3+ non-hematologic event as assessed using Common Terminology Criteria for Adverse Events (CTCAE) CTEP Version 4.0. Here, the number of patients reporting a DLT are reported
measure
Number of Patients Reporting Dose-Limiting Toxicity (DLT) (Phase I)
time Frame
After one 28 day cycle
description
Patients were assessed using the Cheson et al. Revised Response Criteria for Malignant Lymphoma (Cheson, et al 2007). A Complete Response (CR) was defined as the disappearance of all evidence of disease, no palpable nodules and bone marrow cleared on biopsy. A Partial Response (PR) was defined as regression of measureable disease and no new sites, with a 50% decrease in sum of the products of dimension (SPD) of nodal masses, and no increase in spleen or liver size. Patients with Waldenstrom's Macroglobulinemia were eligible to be evaluated as a Minor Response (MR) in which a reduction between 25% and 50% of serum monoclonal IgM was observed. A Progression (PD) was defined as having any new lesions or a 50% increase in the SPD of any previously involved nodes. A Stable Disease (SD) is the absence of any of the previously defined responses.
measure
Best Response to Dose Level 0
time Frame
Up to 5 years

secondary Outcomes

description
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.
measure
Overall Survival for All Eligible Patients
time Frame
Up to 5 years
description
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. The distribution of progression-free survival time will be estimated using the method of Kaplan-Meier.
measure
Progression-Free Survival For All Eligible Patients
time Frame
Up to 5 years
description
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented.
measure
Duration of Response for All Eligible Patients
time Frame
Up to 5 years
description
Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.
measure
Time to Treatment Failure for All Eligible Patients
time Frame
Up to 5 years

Full study description

brief Summary: RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving everolimus together with lenalidomide may be an effective treatment for lymphoma. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving everolimus and lenalidomide together and to see how well they work in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma.
detailed Description: PRIMARY OBJECTIVES: I.Phase I: To establish the maximum tolerated dose of EVEROLIMUS and lenalidomide in subjects with relapsed/refractory Non-Hodgkin Lymphoma or Hodgkin Lymphoma. II. Phase II: To assess tumor response to EVEROLIMUS and lenalidomide in subjects with relapsed/refractory Non-Hodgkin Lymphoma or Hodgkin Lymphoma. SECONDARY OBJECTIVES: I. To evaluate overall survival, progression-free survival, duration of response, and time to treatment failure of subjects receiving EVEROLIMUS and lenalidomide. II. To describe the adverse event profile (using CTCAE CTEP Version 4.0) of EVEROLIMUS and lenalidomide. OUTLINE: Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-1b3b0ce53f0bb59da4f6
requested nct id
NCT01075321
primary nct id
NCT01075321
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Peripheral+T-Cell+Non-Hodgkin+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
payload sha256
cb521354012dc3a80da803973c870eee9dd5a383bf5feae11ee11b1fc89408f5
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-1b3b0ce53f0bb59da4f6
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01075321
occurrences
context exact
NCT01075321
end
11
exact text
NCT01075321
start
0
offset unit
unicode_code_points
query cond
Peripheral T-Cell Non-Hodgkin Lymphoma
query disease state id
ds-peripheral-t-cell-non-hodgkin-lymphoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
source file sha256
e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
source json pointer
/studies/133/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c1e917efc38a8e00b600d7ef783f26197cb57e7e70520a8572789ff2fda179d3
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Peripheral+T-Cell+Non-Hodgkin+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-e2ae5b878f22197d8202
requested nct id
NCT01075321
primary nct id
NCT01075321
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ
source record id
Source null
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
payload sha256
b115f892c28577c020c7471235ffb2f0c2b20380e710eeeb6498c1fc402f5029
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-e2ae5b878f22197d8202
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01075321
occurrences
context exact
NCT01075321
end
11
exact text
NCT01075321
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-001.json
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
source json pointer
/studies/13/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c1e917efc38a8e00b600d7ef783f26197cb57e7e70520a8572789ff2fda179d3
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ

Preserved source evidence · Not medical advice